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Letter to Editor
To the Editor,
We report the case of a 16-year-old young boy who presented 
with	a	single	episode	of	generalized	fit	in	the	casualty.	The	
patient had generalized tonic-clinic seizure lasting for a minute 
followed	by	post	ictal	drowsiness	at	presentation.	He	did	not	
have	 any	 history	 of	 seizures	 in	 the	 past	 or	 any	 significant	
family history. On examination, there were no lateralizing 
signs or neck rigidity. Magnetic resonance imaging of the 
brain and electroencephalogram were normal. The patient was 
loaded with intravenous phenytoin at a dose of 20 mg/kg body 
weight.	He	was	discharged	on	tablet	phenytoin	300	mg	daily.	
Two months following that, the patient presented with 
moderate to high grade fever, muscle aches, and joint pains 
involving both small and large joints of the body for a week. 
There was no past history of photosensitivity, joint pains, or 
oral ulcers. On physical examination, malar rash was present 
[Figure 1]. There was no visible joint swelling or redness. 
His	 routine	 blood	 investigations	 revealed	 hemoglobin	 of	
13.4 g/dL, total leukocyte count of 7800/mm3, platelet count 
of 180,000/mm3, high erythrocyte sedimentation rate of 
56 mm/h, and C-reactive protein of 11.6 mg/L. Renal, liver, 
and thyroid function tests and urinalysis were normal. Urine 
and blood cultures were sterile. Chest X-ray and abdominal 
ultrasound examination were normal. Rheumatoid factor 
and complement levels were also normal; Coomb’s test 
was negative. Antinuclear antibody (ANA) test by indirect 
immunofluorescence	 assay	was	 positive	 in	 a	 titer	 of	 1:160	
in a homogenous pattern. Antihistone antibodies were also 
strongly positive, whereas double-stranded DNA antibody test 
was	negative.	Cerebrospinal	fluid	examination	was	normal.	
The patient was started on levetiracetam and phenytoin was 
rapidly	tapered	off.	He	was	managed	on	non	steroidal	anti‑
inflammatory	drugs	 and	 corticosteroids.	He	was	given	oral	
prednisolone at a dose of 1 mg/kg/day for the next few weeks 
followed by gradual dose reduction. The patient responded 
well to the treatment, his symptoms resolved, and he was 
discharged.	Repeat	testing	of	autoimmune	profile	at	6	weeks	
showed	 improvement	 in	ANA	 titer	 (1:80)	 and	 negative	
antihistone antibodies.
Like most antiepileptic drugs, phenytoin has also been 
implicated in drug-induced lupus erythematosus (DILE). 
However,	 the	data	has	been	scarce,	with	very	 few	reported	
cases so far.[1] The underlying pathophysiology is yet unclear. 
Various mechanisms have been proposed including slow 
acetylation, graft versus host-like reaction, and inhibition 
of methylation on T cells.[1-4] DILE commonly presents with 
musculoskeletal complaints such as myalgias and nonerosive 
arthritis.[5,6] Cutaneous manifestations including malar rash 
and renal involvement are seen less frequently in DILE as 
compared to idiopathic systemic lupus erythematosus.[5,6] 
Common serological tests in DILE include elevated ANA titer 
with a homogenous pattern and positive antihistone antibodies 
in >75% of patients.[7] On the other hand, double-stranded 
DNA antibodies occur in <5% of patients with DILE.[7] Early 
diagnosis of DILE and appropriate treatment can prevent fatal 
complications.
Declaration of patient consent
The authors certify that they have obtained all appropriate 
patient consent forms. In the form the patient(s) has/have 
given his/her/their consent for his/her/their images and other 
clinical information to be reported in the journal. The patients 
understand that their names and initials will not be published 
and due efforts will be made to conceal their identity, but 
anonymity cannot be guaranteed.




Abhishek Juneja, Kuljeet Anand
Department of Neurology, Dr. RML Hospital, New Delhi, India
Address for correspondence: Dr. Abhishek Juneja, 
Department of Neurology, Dr RML Hospital, New Delhi, India. 
E‑mail: drabhishekjuneja@gmail.com
Phenytoin‑Induced Lupus Erythematosus in a Young Child
Figure 1: A young male patient with malar rash
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